Vatiquinone + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Dec 17, 2020 → Oct 2, 2023
NCT ID
NCT04577352About Vatiquinone + Placebo
Vatiquinone + Placebo is a phase 2/3 stage product being developed by PTC Therapeutics for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT04577352. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
15
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04577352 | Phase 2/3 | Completed |
Competing Products
20 competing products in Friedreich Ataxia